

Abnormal lymphatic S1P signaling aggravates lymphatic dysfunction and tissue inflammation

Dongeon Kim^{1,2,#}, Wen Tian^{1,2,#}, Timothy Ting-Hsuan Wu^{2,3}, Menglan Xiang^{1,2}, Ryan Vinh^{1,2}, Jason Chang^{1,2}, Shenbiao Gu^{1,2}, Seunghee Lee^{1,2}, Yu Zhu^{1,2}, Torrey Guan^{1,2}, Emilie Claire Schneider^{1,2}, Evan Bao^{1,2}, J. Brandon Dixon⁴, Peter Kao², Junliang Pan^{1,2}, Stanley G. Rockson², Xinguo Jiang^{1,2,*}, and Mark Robert Nicolls^{1,2,*}.

¹VA Palo Alto Health Care System, Palo Alto, California, USA.

²Stanford University School of Medicine, Stanford, California, USA.

³Department of Biochemistry, Stanford Bio-X, Stanford, California, USA.

⁴Georgia Institute of Technology, Atlanta, Georgia, USA

These authors contributed equally to this work

*To whom correspondence may be addressed. E-mail: mnicolls@stanford.edu; xinguoj@stanford.edu

17 **Abbreviations**

18 **LEC:** Lymphatic endothelial cell
19 **S1P:** Sphingosine-1-phosphate
20 **SPHK1:** Sphingosine kinase 1
21 **S1PR1:** S1P receptor 1
22 **APC:** Antigen-presenting cell
23 **LN:** Lymph node
24 **T_{RM}:** Tissue-resident memory T
25 **Th1/2:** T helper type 1/2 cells
26 **Tregs:** Regulator T cells
27 **LYVE1:** Lymphatic vessel endothelial receptor 1
28 **Prox1:** Prospero homeobox 1 (Prox1)
29 **NIR:** Near-infrared
30 **HDLEC:** Human dermal LEC
31 **FACS:** Fluorescence-activated cell sorting
32 **WT:** Wild type
33 **S1pr1^{LECKO}:** Lymphatic endothelial cell-specific *S1pr1* knockout
34 **IL:** Interleukin
35 **IFN:** Interferon
36 **4-DP:** 4-deoxypyridoxine
37 **CLA:** Cutaneous lymphocyte-associated antigen
38 **PSGL-1:** P-selectin glycoprotein ligand-1

BACKGROUND: Lymphedema is a global health problem with no effective drug treatment. Enhanced T cell immunity and abnormal lymphatic endothelial cell (LEC) signaling are promising therapeutic targets for this condition. Sphingosine-1-phosphate (S1P) mediates a key signaling pathway required for normal LEC function, and altered S1P signaling in LECs could lead to lymphatic disease and pathogenic T cell activation. Characterizing this biology is relevant for developing much-needed therapies.

METHODS: Human and mouse lymphedema was studied. Lymphedema was induced in mice by surgically ligating the tail lymphatics. Lymphedematous dermal tissue was assessed for S1P signaling. To verify the role of altered S1P signaling effects in lymphatic cells, LEC-specific *S1pr1*-deficient (*S1pr1*^{LECKO}) mice were generated. Disease progression was quantified by tail-volumetric and -histopathological measurements over time. LECs from mice and humans, with S1P signaling inhibition, were then co-cultured with CD4 T cells, followed by an analysis of CD4 T cell activation and pathway signaling. Finally, animals were treated with a monoclonal antibody specific to P-selectin to assess its efficacy in reducing lymphedema and T cell activation.

RESULTS: Human and experimental lymphedema tissues exhibited decreased LEC S1P signaling through S1PR1. LEC *S1pr1* loss-of-function exacerbated lymphatic vascular insufficiency, tail swelling, and increased CD4 T cell infiltration in mouse lymphedema. LECs, isolated from *S1pr1*^{LECKO} mice and co-cultured with CD4 T cells, resulted in augmented lymphocyte differentiation. Inhibiting S1PR1 signaling in human dermal LECs (HDLECs) promoted T helper type 1 and 2 (Th1 and Th2) cell differentiation through direct cell contact with lymphocytes. HDLECs with dampened S1P signaling exhibited enhanced P-selectin, an important cell adhesion molecule expressed on activated vascular cells. *In vitro*, P-selectin blockade reduced the activation and differentiation of Th cells co-cultured with sh*S1PR1*-treated HDLECs. P-selectin-directed antibody treatment improved tail swelling and reduced Th1/Th2 immune responses in mouse lymphedema.

CONCLUSION: This study suggests that reduction of the LEC S1P signaling aggravates lymphedema by enhancing LEC adhesion and amplifying pathogenic CD4 T cell responses. P-selectin inhibitors are suggested as a possible treatment for this pervasive condition.

Keywords: Lymphedema, Lymphatic endothelial cells (LECs), Sphingosine-1-phosphate receptor 1 (S1PR1), P-selectin, and CD4 T cells.

74 **Clinical Perspective**

75 **What is New?**

- 76 ● Lymphatic-specific *S1pr1* deletion exacerbates lymphatic vessel malfunction and
- 77 Th1/Th2 immune responses during lymphedema pathogenesis.
- 78 ● *S1pr1*-deficient LECs directly induce Th1/Th2 cell differentiation and decrease anti-
- 79 inflammatory Treg populations.
- 80 ● Peripheral dermal LECs affect CD4 T cell immune responses through direct cell
- 81 contact.
- 82 ● LEC P-selectin, regulated by S1PR1 signaling, affects CD4 T cell activation and
- 83 differentiation.
- 84 ● P-selectin blockade improves lymphedema tail swelling and decreases Th1/Th2
- 85 population in the diseased skin.

86 **What Are the Clinical Implications?**

- 87 ● S1P/S1PR1 signaling in LECs regulates inflammation in lymphedema tissue.
- 88 ● S1PR1 expression levels on LECs may be a useful biomarker for assessing
- 89 predisposition to lymphatic disease, such as at-risk women undergoing mastectomy
- 90 ● P-selectin Inhibitors may be effective for certain forms of lymphedema
- 91

Introduction

Lymphedema is a chronic state of lymphatic vascular insufficiency characterized by regionally impaired immunity, interstitial edema, adipose deposition, and fibrotic remodeling. The condition affects around 100-200 million individuals globally but has no effective pharmacological therapies^{1,2}. Secondary lymphedema is the predominant form of the disease, resulting from acquired lymphatic vascular damage arising after parasitic infection, oncologic conditions, cancer therapy, chronic venous disease, and trauma. Research from the past two decades suggests that pathologically skewed CD4⁺ T cell differentiation promotes preclinical lymphedema^{3,4}. While blocking Th2 immunity or inflammation, in general, improves skin histopathology, this therapy is ineffective for reducing limb volumes⁵. These studies demonstrate the relevance of abnormal immunity to lymphedema in a way that may inform therapeutic design.

By producing molecules such as S1P, adhesion proteins, and CCL21, lymphatic endothelial cells (LECs) facilitate the lymphatic transport of tissue fluid, antigens, and antigen-presenting cells (APCs) to draining lymph nodes (LNs)⁶⁻⁸. Emerging studies show that LECs are critical immune cell modulators⁹⁻¹¹. For example, LECs regulate T cell activation and immune tolerance in peripheral tissue through the programmed cell death protein-ligand inhibitory pathway and MHC I/II complexes^{9,12-14}; LECs also inhibit the maturation of dendritic cells by dampening their ability to activate effector T cells¹⁵. Unlike the better-understood roles of LEC-centered lymphangiogenesis and lymph trafficking in lymphedema, the action of these vascular cells in disease-associated inflammation is less well understood.

Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite involved in many cellular processes, including differentiation, survival, migration, angiogenesis, and lymphangiogenesis¹⁶⁻¹⁹. It exerts biological effects through binding and activating five closely related G-protein coupled receptors, namely, S1P receptor (S1PR) 1, 2, 3, 4, and 5²⁰. S1P signaling, via S1PR1 in vascular endothelial cells, promotes restoration of vascular integrity and induces cell-cell adhesion between pericytes and endothelial cells²¹⁻²⁴. S1PR1 is the most highly expressed isoform in LECs and is a necessary receptor to prevent lymphatic hypersprouting and promote lymphatic maturation^{18,25,26}. While various types of cells synthesize S1P, endothelial cells, including blood and lymphatic endothelial cells, are generally considered as major producers¹⁸. S1P generation is controlled by sphingosine kinases SPHK1 and SPHK2, with the former enzyme playing the more dominant role. A prior study shows that SPHK1 expression and the lyase that degrades S1P are significantly downregulated in mouse lymphedema²⁷, raising the possibility that S1P signaling abnormality may promote lymphedema development.

In this study, we showed that LEC S1PR1 expression was low in both clinical and pre-clinical lymphedema skin. Using LEC-specific *S1pr1* loss-of-function transgenic mouse lines (*S1pr1*^{LECKO}), we found that lymphatic *S1pr1* deficiency exacerbates lymphedema. Cell culture studies demonstrated that LECs with reduced S1PR1 skewed T cell differentiation towards T helper 1/2 (Th1/Th2) phenotypes in a contact-dependent manner. Bulk mRNA-Sequencing analysis revealed that S1P signaling deficiency enhanced LEC expression of P-selectin, an adhesion molecule regulating T cell trafficking and activity²⁸. Blocking P-selectin attenuated Th1/Th2 differentiation induced by *S1PR1*-deficient LECs in culture; anti-P-selectin antibody treatment decreased tail swelling and reduced Th1/Th2 cell population in lymphedema skin of *S1pr1*^{LECKO} mice. Collectively, we describe how lymphedema-associated immune dysregulation may be linked to reduced LEC S1P signaling and how P-selectin inhibitors, already approved for use in other diseases, may be effective in this otherwise refractory condition.

Methods

All data and methods used in analysis will be made available to any researcher upon reasonable request.

Mice. All mice were purchased from Jackson Laboratory. Detailed mice information: C57BL/6J (B6, JAX:000664), Prox1tm3(cre/ERT2)Gco/J (Prox1-Cre-ER^{T2}, JAX:022075), B6.129S6(FVB)-S1pr1tm2.1Rlp/J (S1P^{1loxP}, JAX:019141), and B6.Cg Gt(ROSA)26Sor^{tm14(CAG-tdTomato)Hze}/J (Ai14(RCL-tdT)-D, JAX:007914). To generate lymphatic endothelial-specific S1pr1-deficient transgenic strain, mice expressing Prox1-Cre-ER^{T2} were crossed with S1PR1^{loxP} mice. Prox1-Cre-ER^{T2} alone littermates were used as WT controls. To generate lymphatic endothelial-specific tdTomato reporter mice (Prox1-Cre-ER^{T2}-tdTomato), Prox1-Cre-ER^{T2} mice were crossed with tdTomato mice. 250mg/kg tamoxifen was subcutaneously injected to 8 weeks mice for 3 consecutive days to activate the Cre-loxP system.

Study approval. Investigation of human tissues in this study was approved by the Stanford University Institutional Review Board (IRB Protocol 7781). The samples were derived from adult patients with chronic primary and acquired lymphedema. Tissue specimens consisted of two contiguous 6-mm full-thickness cutaneous punch biopsy specimens obtained from a lymphedema-affected limb, with similar specimens obtained from the unaffected contralateral limb serving as control specimens. The diagnosis of lymphedema for each subject was clinically ascertained in the Stanford Center for Lymphatic and Venous Disorders. Phlebotomy samples for quantitation of serum S1P levels were obtained from lymphedema subjects and healthy controls; studies using these phlebotomy specimens were approved by the Stanford University Institutional Review Board (IRB Protocol 17690). Human buffy coats were purchased from Stanford Blood Center. All animal studies were approved by the VA Palo Alto Institutional Animal Care and Use Committee (IACUC).

The mouse-tail model of acquired lymphedema. Lymphedema was induced through ablation of major lymphatic trunks on both sides of the tail and dermal lymphatic capillaries. Tail skin incision was made ~2 cm from the mouse tail base. For surgical sham controls, skin incision alone was performed. Disease progression was quantified by volumetric and histopathological measurements. Lymphatic vessel functions were analyzed with a near-infrared (NIR) imaging system.

Tail volume measurement. Mice tail images were taken through digital photographic technique preoperatively (D0) and postoperatively (D7, 14, and 21) using an Olympus D-520 Zoom digital camera at a fixed distance from the subject (37cm). Digital photographic tail images were quantified using Adobe Photoshop ruler tool. Tail volumes were derived from measurement of the tail diameter using the truncated cone approximation method (**Figure S1**).

Quantification of S1P with liquid chromatography tandem mass spectrometry (LC-MS/MS)

Briefly, S1P was separated from serum with an ACE reverse phase C18 HPLC column. Formic acid 0.5% in 5mM NH₄Ac (A) and formic acid 0.5% in acetonitrile/water (9/1) (B) were used as the mobile phase. Lipids were detected with positive multiple reaction monitor (MRM) scanning at 330.20/264.40 m/z for S1P using a Sciex API-4000 MS/MS combined with a Shimadzu 20A HPLC system. The internal standard for this method was Carbutamide. The quantification limit was 1 ng/ml. The calibration range was 1-2000ng/ml. The accuracy of the standards and control samples ranged from 88.7% to 120%. The information of patients was described in **Table S1 and S2**.

Lymphatic drainage and leakiness test by NIR imaging. The lymphatic vessel transportation function and leakage were characterized by using a NIR lymphatic imaging system and dye quantification at day 21. The collecting lymphatic function was tracked throughout the procedure by imaging the dynamics of transport of a 10 μ l ICG (10mM) injected intradermally, at the tip of the mouse tail. NIR images were taken 10 minutes after dye injection using a custom NIR imaging system as described in detail in the previous study^{29,30}. ImageJ was used for the quantification of NIR dye leakage. Specifically, the relative intensity of leaked ICG was determined in two steps: 1) total leaked NIR intensity from each tail was calculated and averaged; 2) intensity was then normalized to control (which was set to 1).

Embryo lymphatic development study. 2 mg tamoxifen was injected intraperitoneally (i.p.) to pregnant mice (*Prox-1-Cre^{ERT2}* x *S1pr1^{fl/-}* mated with *Prox-1-Cre^{ERT2}* x *S1pr1^{fl/-}*) at E10.5 and E11.5 as previously described²⁹. Embryos were harvested at E17.5. Brightfield images were taken by using MVX10 microscope. Dorsal areas of embryonic skin were harvested for lymphatic vascular evaluation.

Immunofluorescence (IF) staining. Surgery sites of 10 μ m tail frozen sections were used for immunohistochemistry. Tail tissues were snap-frozen in O.C.T. compound solution (Fisher Healthcare) for IF staining and paraffin-embedded for hematoxylin and eosin (H&E) staining. Anti-LYVE1 (1:50; LSBio) Ab for lymphatic vessels and anti-CD4 (1:50; Abcam) Ab for CD4 T cell were stained at 4°C overnight. Secondary antibodies were labeled with the Alexa Fluor 488 or Cy3 for 1h at room temperature (1:400; Invitrogen). Photomicrographs were acquired using LEICA DMI8 or Zeiss LSM710. ImageJ was used to quantify for lymphatic areas.

Real-time reverse transcription quantitative PCR (RT-qPCR). Total RNA was isolated from mouse tail skin using the RNeasy® Fibrous Tissue Mini Kit (QIAGEN) and from HDLECs using RNeasy® Mini Kit (QIAGEN) according to the manufacturer's instructions. Total RNA was synthesized to complementary DNA using the High-Capacity cDNA Reverse Transcription Kits (Appliedbiosystems) following the manufacturer's protocol. RT-PCR was performed using PowerSYBR Green PCR Master Mix (Applied Biosystems) according to the manufacturer's instructions. The amplification condition was set at 40 cycles at 95°C for 15s and 60°C for 60s using AMI Prism® 7900HT Sequence detection System (Applied Biosystems). The sequences of the primers used for RT-qPCR are listed in **Table S3 and S4**.

CD4⁺ T cell isolation. Naïve CD4⁺ T cells from the spleens of C57BL/6 WT mice were purified with Naïve CD4⁺ T cell Isolation Kit according to the manufacturer's (Miltenyi Biotec) instructions. Peripheral blood mononuclear cells (PBMCs) were purified from buffy coats by gradient centrifugation with histopaque (density: 1.077 g/ml). Naïve CD4 T cells were purified from PBMCs using EasySep Human Naïve CD4⁺ T cell Isolation Kit II (STEMCELL Technologies). Memory CD4 T cells were purified from PBMCs using EasySep Human Memory CD4⁺ T cell Isolation Kit (STEMCELL Technologies).

LEC purification and culture. Axillary, bronchial, and lingual LNs were isolated from WT and *S1pr1^{LECKO}* mice. LNs were digested with the multi-tissue dissociation Kit I and gentle MACS Octo Dissociator with Heaters (Miltenyi Biotec). Digested lymph node stromal cells were cultured in endothelial cell growth medium II supplemented with 2% fetal calf serum, 100 U/mL of penicillin, 100 g/mL of streptomycin, and growth supplements including epidermal growth factor (5ng/ml), basic fibroblast growth factor (10ng/ml), insulin-like growth factor (20 ng/ml), vascular endothelial growth factor 165 (0.5 ng/ml), heparin (22.5 μ g/ml), and hydrocortisone (0.2 μ g/ml). After five days of culture, cells of CD45⁻, CD31⁺, and Gp38⁺ were selected as LEC population. Cells were sorted by fluorescence-activated cell sorting (FACS) Aria III. LECs used in experiments showed over 99% purity.

Co-culture of CD4⁺ T cells with LECs. Purified LECs were cultured in a 24-well plate (4 x 10⁴/well). After overnight adhesion, 2 x 10⁵ mouse naïve CD4⁺ T cells and APCs along with anti-CD3 and CD28 monoclonal antibodies (BD Biosciences; 3 µg/ml) were added and cultured for 3 days in RPMI-1640 supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C in a humidified 5% CO₂ atmosphere. Commercially-purchased HDLECs (PromoCell) were cultured in a 24-well plate (4 x 10⁴/well). After overnight adhesion, 2 x 10⁵ human naïve CD4⁺ T cells with ImmunoCult™ Human CD3/CD28 T cell Activator (STEMCELL Technologies) were added and cultured for 3 days in RPMI-1640 supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C in a humidified 5% CO₂ atmosphere.

Flow cytometry analysis. Single-cell suspension prepared from mice tail skin digested with multi tissue dissociation Kit I or from ex vivo cultures were analyzed by intracellular cytokine staining as previously described^{31,32}. Prepared cells were restimulated with Cell Stimulation Cocktail (plus protein transport inhibitors) (ThermoFisher Scientific) for 5 h at 37°C in a humidified 5% CO₂ atmosphere. After stimulation, the cells were stained with fluorescein-conjugated antibodies against Fixable Viability Dye (Invitrogen), CD4, CD8, CD25, and CD44 (BD Bioscience). Following surface staining, Foxp3, IFN-γ, IL-4, and IL-17A were intracellularly stained using fixation/permeabilization buffer (eBioscience) according to the manufacturer's instructions. Additionally, CD31, CD45, CD69, CD103, Gp38, and S1PR1 fluorescein-conjugated antibodies were used for surface staining. Isotype-matched antibodies were used as isotype controls. **Table S5** summarize the Ab information.

Cytokine profiling. The supernatant co-cultured human CD4 T cell with HDLEC was collected at day 3. T cell related-cytokine assay was performed in EVE technologies.

Analysis of bulk mRNA sequencing (bulk RNA-seq) data. Total RNA was isolated from HDLECs using the RNeasy® Plus Mini Kit (QIAGEN) according to the manufacturer's instructions. mRNA library was formed by ploy A enrichment and reverse transcription of cDNA. Illumina PE150 technology is processed to sequence the sample (Novogene). Sequencing reads were aligned to the Human GRCh38 reference genome according to the ENCODE uniform processing pipeline, by STAR (v2.1.3) then quantified with RSEM (v1.4.1). Differential gene expression analysis was performed in R using EBSeq package, an empirical Bayes hierarchical model for inference in RNA-seq experiments, using false discovery rate (FDR) of 0.05 to retrieve list of differentially expressed genes (DEGs). Differentially expressed genes were ranked by posterior fold change and enriched for gene sets using The Molecular Signatures Database (MSigDB) and Gene Set Enrichment Analysis (GSEA) tools developed by the Broad Institute.

Statistics. All data are presented as a mean ± SEM. Nonparametric Mann-Whitney test and Wilcoxon matched-pairs signed rank test were used for statistical analyses using GraphPad Prism v9.3.1. For comparisons between multiple experimental groups, Ordinary one-way ANOVA followed by Dunn's multiple comparisons test for post hoc analyses were used after normal distribution test. p < 0.05 was considered statistically significant. Error bars correspond to the mean with SEM.

Results

Lymphedema is characterized by decreased LEC S1PR1-mediated S1P signaling

LEC S1P signaling through S1PR1 is critical for lymphatic homeostasis and repair²⁶. To determine the relevance of LEC S1P/S1PR1 signaling in lymphedema, we used a mouse tail lymphedema model, in which tail skin incision and lymphatic trunk ablation were performed for surgical induction of lymphedema (**Figure 1A**). Real-time reverse transcription quantitative PCR (RT-qPCR) analysis of *Sphk1*, the key gene involved in S1P production, demonstrated a reduction of the expression in lymphedematous mouse skin (**Figure 1B**), confirming our prior microarray study²⁷. LECs are the major cell type in the skin that produces S1P, a process reliant on SPHK1 activity^{26,33-35}. LECs in lymphedema tissues express decreased SPHK1 (**Figure 1C, 1D, and S2A**). S1PR1 is the most strongly expressed S1P receptor in LECs, and S1PR1 signaling is necessary for lymphatic vessel maturation²⁶. A diminished *S1pr1* mRNA level was detected in lymphedema tail skin (**Figure 1E**). More specifically, we analyzed S1PR1 expression in Gp38⁺CD31⁺ cells using flow cytometry and found significantly decreased S1PR1 expression in LECs in lymphedema skin (**Figure 1F and 1G**). Next, we assessed S1P serum concentration in preclinical and clinical lymphedema. Decreased S1P production was detected in the lymphedema condition compared with the healthy control in both mouse and human (**Figure 1H, 1I, and S2B**). Consistent with mouse lymphedema tail skin, the expression of S1PR1 was decreased in Gp38⁺ lymphatic vessel of human lymphedema skin (**Figure 1J and 1K**). These data demonstrate that LEC S1P/S1PR1 signaling is reduced in both human and preclinical lymphedema.

Lymphatic *S1pr1* deficiency promotes lymphatic dysfunction in lymphedema.

To evaluate lymphatic-specific S1P/S1PR1 signaling in lymphedema pathogenesis, we generated LEC-specific *S1pr1*-deficient (*S1pr1*^{LECKO}) mice by crossing *S1pr1*^{fl/fl} mice with transgenic mice expressing Cre-ERT2 under the control of the Prox-1 promoter (*Prox-1-Cre*^{ERT2}). Assessment of LEC (Gp38⁺CD31⁺) S1PR1 expression demonstrated >75% knockout efficiency (**Figure S3**). *S1pr1*^{LECKO} mice were subjected to lymphedema surgery three weeks following tamoxifen treatment (**Figure 2A**). Serial evaluation of tail volumes following lymphedema surgery showed that genetic silencing of LEC-specific *S1pr1* exacerbated tail swelling compared with WT littermate control mice (**Figure 2B and 2C**). Sham surgery, which only involves skin incision, did not cause tail swelling in both WT and *S1pr1*^{LECKO} mice (**Figure S4**). The mouse lymphedema model is characterized by severe cutaneous thickening and the lymphatic area increase in affected tails (**Figure 2D**). H&E staining of cross-sections demonstrated increased cutaneous thickness and lymphatic area in tissues derived from *S1pr1*^{LECKO} mice (**Figure 2E through 2G**). Immunofluorescence (IF) staining similarly demonstrated areas of increased lymphatic capillaries identified by LYVE1 positivity in tail samples from *S1pr1*^{LECKO} mice (**Figure 2H and 2I**). Additionally, proliferation marker Ki-67⁺ cells in LYVE-1⁺ cells were elevated in lymphatic *S1pr1*-deficient mice with lymphedema comparing to that of the WT control, suggesting that augmented number of LECs contributes to the increase of LYVE1⁺ lymphatic vascular area (**Figure S5**). Because the dilated lymphatic vessels have been related to decreased transport functionality of lymphatic vasculature, an evaluation of lymphatic vessel transport function was performed by using near-infrared (NIR) imaging system. The indocyanine green (ICG) was injected intradermally at the end of the mouse tail and NIR images were captured through side- and top-down views (**Figure 2J**). In line with the tail volume assessment, lymphatics of *S1pr1*^{LECKO} mice subjected to lymphedema surgery exhibited decreased lymphatic drainage and increased lymphatic leakage (**Figure 2K and 2L**). Together, these data suggest that loss of lymphatic S1P/S1PR1 signaling causes a more severe decline of lymphatic function and worsens lymphedematous tissue swelling. Pathways critical for lymphatic repair in disease conditions also play important roles in lymphatic development¹⁸; however, assessment of LEC S1P/S1PR1 signaling during early embryonic stage illustrated only minimal dorsal

edema (**Figure S6**), indicating S1P signaling through S1PR1 is not crucial for early lymphatic development characterized by lymphangiogenesis. This study also suggests that in pathological conditions, LEC S1PR1 signaling may regulate other biological processes beyond lymphangiogenesis.

LEC *S1pr1* deficiency increases CD4 T cell infiltration.

CD4 T cells regulate lymphedema pathology by inhibiting lymphatic vessel pumping capacity, decreasing collateral lymphatic formation, and increasing lymphatic leakage^{3,4,36,37}. Prior studies demonstrated that LECs regulate T cell differentiation^{11,38,39}. We hypothesized that LEC *S1pr1* deficiency skews pathological T cell differentiation in lymphedema. Flow cytometric analyses of single-cell suspension of lymphedematous tissues harvested from WT and *S1pr1*^{LECKO} mice were performed, and the T cell populations were assessed (**Figure 3A and S7**). There was an increased accumulation of CD45⁺ immune cells in the tail skin of *S1pr1*^{LECKO} as compared with WT skin following lymphedema surgery (**Figure 3B**). Further analysis demonstrated that lymphedema tissue from *S1pr1*^{LECKO} mice contained significantly more CD4⁺ T cells compared with WT littermate controls, but not CD8⁺ T cells (**Figure 3C and 3D**). We focused our analysis on CD4 T cells subsets⁴⁰⁻⁴² and demonstrated increased IFN- γ -producing Th1 cells and interleukin (IL)-4-expressing Th2 cells (**Figure 3E and 3F**), and decreased Foxp3⁺CD25⁺ regulatory T cells (Tregs) (**Figure 3G**) in lymphatic *S1pr1*-deficient lymphatic mice. Recent research shows that tissue-resident memory CD4⁺ (T_{RM}) cells are associated with vasculitis pathogenesis^{43,44} and we observed increased both CD4 T_{RM} and CD4 non-T_{RM} cell populations in *S1pr1*^{LECKO} lymphedema tail skin (**Figure S8A and S8B**). Evaluation of IL-4-producing CD103⁺CD4⁺ T_{RM} cells demonstrated a significant increase of this population in *S1pr1*^{LECKO} lymphedema tissues (**Figure S8C through S8E**), indicating CD4⁺ T_{RM} cells comprise an important source of CD4 T cells in a more severe form of experimental lymphedema. An IF study demonstrated increased numbers of CD4 T cells located in close proximity to lymphatic vessels in lymphedema tissue from *S1pr1*^{LECKO} mice (**Figure 3H and 3I**). These results suggest that LEC *S1pr1* deficiency may attract more CD4 T cells to lymphatic cells and promote pathological differentiation and expansion of these T cells in lymphedema.

LEC S1P/S1PR1 signaling regulates CD4 T cell differentiation.

Emerging evidence demonstrates the LEC's ability in regulating adaptive immune responses³⁹. To assess whether LEC S1P signaling deficiency preferentially skews CD4 T cell differentiation toward certain Th pathways, LEC-dependent CD4 T cell activation and differentiation assays were performed. Mouse lymph node-LECs (mLN-LECs) were sorted by FACS by selecting CD45(-) population that expresses both Gp38 and CD31 (**Figure 4A**). The purity of mLN-LECs was approximately 99% after sorting (**Figure 4B**). Sorted LECs were co-cultured with mouse splenocyte-derived naïve CD4 T cells in the presence of anti-CD3/28 antibodies (Ab) stimulation for 4 days (**Figure 4C**). *S1pr1*-deficient LECs significantly enhanced IFN- γ and IL-4 production in T cells (**Figure 4D and 4E**), while reducing the relative Foxp3⁺CD25⁺ population (**Figure 4F**). These results suggest that *S1pr1*-deficient LECs preferentially promote Th1 and Th2 effector cells and suppress Treg cell differentiation.

Because LECs have tissue-specific tolerogenic properties^{45,46}, we tested whether LECs from peripheral tissues also exhibit immunomodulatory function. We used lentiviral vectors that express short hairpin RNA targeting *S1PR1* (sh*S1PR1*) to knockdown S1PR1 in primary human dermal LECs (HDLECs) (**Figure S9A through S9C**). In HDLECs, *S1PR1* expression is the highest, with S1PR4 and S1PR5 undetectable (**Figure S9D**). We then asked whether

S1PR1 knockdown influences the expression of other detectable *S1PRs* and *SPHKs*. Our data demonstrated that mRNAs of *S1PR2*, *S1PR3*, and *SPHK1* were decreased in HDLECs with *S1PR1* knockdown (**Figure S9E through S9I**). shControl (shCtr)- or sh*S1PR1*-treated HDLECs (sh*S1PR1*-HDLECs) were co-cultured for three days with naïve CD4 T cells, purified from healthy individual peripheral blood mononuclear cells (PBMCs), in the presence of anti-CD3/28 Abs (**Figure 5A and 5B**). CD4 T cells, co-cultured with sh*S1PR1*-HDLECs, generally secreted higher amounts of the Th1 cytokine, IFN- γ , and the Th2 cytokine, IL-4, compared with T cells co-cultured with shCtr-HDLECs (**Figure 5C and 5D**), while reducing Treg (Foxp3⁺CD25⁺) population (**Figure 5E**). Multiplex cytokine measurement of CD4 T cell-related cytokines, IL-2 (T cell proliferation and activation), IFN- γ (Th1), and IL-4/5/13 (Th2) showed that sh*S1PR1*-treated HDLECs significantly increased the cytokine production by CD4⁺ T cells compared with shCtr-HDLECs (**Figure 5F to 5J**). Co-culture of those cells in a *trans*-well system (**Figure 5K**) indicated that the population of IFN- γ ⁺, IL-4⁺, and Foxp3⁺ T cells was similar in shCtr- and sh*S1PR1*-HDLECs (**Figure 5L through 5N**). Taken together, these results suggest that LECs regulate CD4 T cell differentiation via a mechanism which requires cell-cell contact.

Increased S1P signaling alleviates lymphedema development.

Given that LEC-specific *S1pr1* deficiency significantly exacerbates lymphatic function and skews towards inflammatory CD4 immune responses, we asked whether increasing S1P signaling could restore pathological lymphatic remodeling and alleviate lymphedema. We used 4-deoxypyridoxine (4-DP), which inhibits the degradation of S1P by dampening S1P lyase activity. 10m/kg 4-DP was administered intraperitoneally (i.p.) to WT B6 mice daily following lymphedema surgery (**Figure S10A**). 4-DP therapy reduced tail swelling (**Figure S10B and S10C**) and lymphatic remodeling (**Figure S10D and S10E**) in mice with lymphedema. Evaluation of immune cell composition in lymphedema tissue revealed significantly ameliorated Th1/2 immune responses in samples harvested from 4-DP treated mice (**Figure S10F through S10H**). Together, our results indicate that LEC S1P signaling is vital during lymphatic repair and important for the control of local pathological immune responses in lymphedema.

S1P signaling suppresses P-selectin expression in HDLECs.

To identify putative S1P-regulated targets expressed in LECs that regulate T-cell differentiation, we performed bulk RNA-sequencing to characterize the gene expression change in HDLECs following *S1PR1* knockdown. We prepared RNA extraction from *S1PR1* knockdown HDLECs with or without CD4 T cell co-culture (**Figure 6A and 6B**). *SELP*, encoding the adhesion protein P-selectin, is the highest upregulated gene among those commonly upregulated (7 genes; *SELP*, *RGS5*, *DIRAS3*, *ADAMTS18*, *ADRA1D*, *APLN*, *IL33*) in sh*S1PR1*-HDLECs with or without CD4 T cells in the culture (**Figure 6C through 6E**). Differential expression analysis showed a total of 18 upregulated genes in sh*S1PR1*-HDLECs without CD4 T cell co-culture and 111 upregulated in sh*S1PR1*-HDLECs with CD4 T cell co-culture (**Table S6 and S7**). *SELP* was detected in the intersection of 7 overlapping upregulated genes between sh*S1PR1*-HDLECs with or without CD4 T cell co-culture (**Figure S11**). Gene set enrichment analysis showed a significantly modulated pathway with up-regulated genes in shCtr-HDLECs versus sh*S1PR1*-HDLECs with CD4 T cell co-culture and suggested the upregulated genes by S1PR1 knockdown were enriched for genes involved in cell-cell contact and T cell activation (**Figure 6F and Table S8**). Flow cytometry analysis confirmed increased cell surface P-selectin protein expression in HDLECs following *S1PR1* knockdown in sh*S1PR1* multiplicity of infection M.O.I.-dependent manner (**Figure 6G through 6I**). Additionally, we confirmed the expression of lymphatic P-selectin dramatically increases in *S1pr1*^{LECKO} mice compared to that of the WT mice (**Figure 6J and 6K**).

P-selectin blockade inhibits the activation of CD4 T cells co-cultured with *S1PR1*-deficient HDLECs.

Cutaneous lymphocyte-associated antigen (CLA) is a carbohydrate modification form of P-selectin glycoprotein ligand-1 (PSGL-1), which is a high affinity receptor for P-selectin and its expression is up-regulated during T cell activation^{47,48}. These studies suggested that P-selectin engagement of PSGL-1/CLA expressed on T cells may regulate T cell differentiation. Consistent with published studies, the CLA⁺ CD4 T cell population increased following 3 days of culture in the presence of anti-CD3/28 Abs (**Figure S12A**). Blocking PSGL-1/CLA signaling with P-selectin-specific antibody, Waps 12.2, suppressed IFN- γ and IL-4 expression in CD4 T cells co-cultured with sh*S1PR1*-treated HDLECs in an antibody dose-dependent manner (**Figure 7A through 7C**). These data suggest that S1P signaling deficiency induces P-selectin expression which, in turn, mediates enhanced Th1 and Th2 CD4 T cell differentiation.

Anti-P-selectin Ab alleviates lymphedema developed in *S1pr1*^{LECKO} mice.

To assess the relevance of P-selectin in lymphedema, we evaluated the effect of blocking P-selectin in lymphedema pathogenesis. 5 mg/kg anti-mouse P-selectin Ab (RB40.34.4)⁴⁹ was injected intravenously (i.v.; retro-orbital) into *S1pr1*^{LECKO} mice one day before lymphedema surgery, and tail volumes were monitored weekly (**Figure 7D**). *S1pr1*^{LECKO} mice treated with RB40.34.4 showed a significant decrease in tail swelling compared to *S1pr1*^{LECKO} mice treated with control IgG (**Figure 7E and 7F**). A flow cytometry analysis of CD4 T cell populations in lymphedematous tail skin demonstrated significant decrease of IFN- γ and IL-4-producing CD4 T cells in samples derived from mice treated with anti-P-selectin (**Figure 7G**). Although not significant, Treg (CD25^{hi} CD4⁺) population showed a trend of increase in lymphedema mice treated with RB40.34.4 comparing to isotype-treated subjects (Figure 7G). Additionally, lymphedema skin from anti-P-selectin Ab-treated mice contained significantly reduced CLA-expressing CD44⁺ CD4 T cells (**Figure S12B and S12C**). To further evaluate the therapeutic potential of anti-P-selectin, RB40.34.4 was administered 2 days following lymphedema surgery, when tails already developed noticeable swelling. Our data illustrated a trend of tail swelling reduction in lymphedema mice treated with anti-P-selectin antibody comparing to isotype-treated mice (**Figure S13**). Collectively, these data suggest that P-selectin blockade improves lymphatic tissue swelling and pathogenic CD4 T cell accumulation in severe lymphedema.

Discussion

The lymphatic vasculature is an integral circulatory system and crucially influences disease pathophysiology^{7,50-59}. Lymphedema is the prototypical lymphatic vascular disorder that afflicts nearly 200 million individuals globally with no approved drugs⁶⁰. A better understanding of lymphedema pathobiology can identify much-needed therapeutic targets. While inflammation is increasingly recognized as a disease-promoting pathology in lymphedema⁶¹, how uncontrolled abnormal immune responses develop in this disease remains poorly understood. In this study, we showed that impaired S1P signaling in LECs promotes pathogenic CD4 T cell differentiation and exacerbates lymphatic malfunction in lymphedema. These results illustrate how pathological LEC and T cell interactions can contribute to lymphedema progression and how suppressing these intercellular relationships may attenuate the disease.

We first assessed key molecules involved in the S1P signaling in lymphedema conditions. LC/MS analysis demonstrated significantly decreased S1P concentrations in both clinical and preclinical serum samples. Our clinical data also support that serum S1P concentrations are inversely associated with age; notably, menopause as a factor reducing S1P levels⁶². Body mass index (BMI) and metabolic status may also influence S1P concentrations, especially in diabetic patients⁶³. However, how BMI may affect S1P levels in our cohort is unclear because relevant information for control subjects is lacking.

Evaluation of SPHK1, the main SPHK isoform, indicated a diminished expression of this protein in LECs, which is the major S1P producer in peripheral tissues^{34,35}. These data suggest that lymphedema tissues have reduced local S1P production concordant with reduced systemic levels. Additionally, lymphatic vessels in lymphedema tissue exhibited low expression levels of the main isoform of S1P receptors, S1PR1. While our data clearly demonstrate that decreased S1P production may result from diminished SPHK1 expression in LECs, we do not exclude the possibility that reduced SPHK1 in other cell types may also contribute to S1P reduction in lymphedema. Future single cell RNA-Seq may provide more comprehensive information on SPHK1 expression in different cell types in lymphedema and offer additional insights.

We previously demonstrated that the proinflammatory lipid mediator, LTB₄, produced chiefly by macrophages, suppresses SPHK1 expression in blood endothelial cells⁶⁴. Because LTB₄ is pathogenic in lymphedema⁶⁵, LTB₄ may similarly reduce SPHK1 expression in LECs. A recent study shows that inflammation-mediated autophagy induces the degradation of SPHK1, resulting in diminished S1P production in LECs⁶⁶, suggesting the inflammation is generally sufficient to reduce SPHK1 levels. Additionally, LTB₄ suppresses LEC Notch activity⁶⁵; and Notch signaling sustains S1PR1 expression⁶⁷. Thus, increased LTB₄ production in lymphedema may also reduce LEC S1PR1 expression. LTB₄ antagonism for upper extremity lymphedema is currently being evaluated in a Phase II clinical trial (NCT05203835). The data from the current study suggest that lymphedema has diminished lymphatic vessel S1P signaling characterized by the decrease of both the ligand (S1P) production and receptor (S1PR1) expression, possibly as a result of increased levels of proinflammatory mediators generated by cells of the innate immunity, such as macrophages.

To evaluate the biological effects of diminished LEC S1P signaling in lymphedema, we generated the LEC-specific *S1pr1* loss-of-function mice (*S1pr1*^{LECKO}) and found that *S1pr1*^{LECKO} mice develop more severe lymphedema with exacerbated tail swelling, cutaneous thickening, increased lymphatic leakage, and aggravated tissue inflammation. Conversely, enhanced S1P signaling by systemic 4-DP treatment improved tail swelling, lymphatic vascular function, and inflammation. Together, these data indicate that LEC S1P signaling through S1PR1 is crucial for lymphatic vascular repair and the control of

pathological tissue inflammation.

While existing data from both clinical and preclinical studies reveal exuberant inflammation characterized by dysregulated adaptive immune cells infiltration in lymphedema tissues^{3,37}, how malfunctioning adaptive immune responses propagate is not completely understood³⁹. We first compared immune cell compositions in the skin tissue of lymphedema of WT vs *S1pr1*^{LECKO} mice. Our data showed significantly increased Th1 (IFN- γ ⁺CD4⁺) and Th2 (IL-4⁺CD4⁺) cells but decreased immunosuppressive Treg cells (CD4⁺CD25⁺FoxP3⁺) in *S1pr1*^{LECKO} mice comparing to that observed in controls. Because Th1 and Th2 cells are pathogenic in lymphedema, whereas Treg cells are demonstrably protective^{36,68}, our data suggest that LEC *S1pr1* deficiency exacerbates pathogenic inflammatory responses in lymphedema.

Additionally, our immune profiling result demonstrated a significantly increased CD69⁺CD103⁺ [markers for Tissue-resident memory cells (T_{RM})⁶⁹⁻⁷¹], IL-4-producing CD4 T cell population in lymphedema tissue from *S1pr1*^{LECKO} mice, suggesting that LEC *S1pr1* deficiency promotes the expansion of T_{RM} population in lymphedema. T_{RM} cells play critical roles in tissue-specific immune and inflammatory diseases^{72,73} and are associated with vasculitis^{43,44}. LEC *S1pr1* deficiency-associated CD4⁺ T_{RM} expansion may play an important pathogenic role in lymphedema progression. Interestingly, several studies have demonstrated that Th2 immune responses are more critical than Th1 immune responses in lymphedema pathogenesis^{4,5,74}, which appear to support our observation that the dominance of IL-4⁺CD4⁺ T_{RM} cells over IFN- γ ⁺CD4⁺ T_{RM} cells in lymphedema tail skin of *S1pr1*^{LECKO} mice.

Because LECs can directly regulate T cell immunity and are important immunomodulators of peripheral tolerance^{10,39,75,76}, we went on to ask whether LECs with deficient S1P signaling skew T cell differentiation and enhance inflammation in lymphedema. *S1pr1*-deficient LECs isolated from LEC-specific *S1pr1* KO mice promoted mouse Th1/Th2 cell differentiation but decreased the immunosuppressive Treg cell subset. Consistently, co-culture of naïve human CD4⁺ T cells with shCtrl- or sh*S1PR1*-HDLECs illustrated that human LECs with *S1PR1* knockdown similarly enhance human Th1/Th2 T cell differentiation. Using the trans-well system, we further show that LEC-modulated skewed T cell differentiation requires cell-cell contact. Collectively, our data suggests that the loss of S1P signaling may lead to altered expression of certain cell surface proteins, which in turn, affects local T cell differentiation. S1P directly acts on T cells to promote Treg differentiation⁷⁷, a mechanism that may partly explain the reduction Treg population in *S1pr1*^{LECKO} mice. While previous experiments suggested that lymphatic damage-induced CD4 T cell immunity involves dendritic cell (DC) migration to the draining lymph node, immune priming, and T cell trafficking back to the local lymphedematous tissue³⁶, our data suggests that in lymphedema, activation of the pathogenic adaptive immunity may be enhanced by S1P signaling-deficient local LECs.

To find genes involved in T cell reprogramming by S1P signaling-deficient LECs, we performed bulk RNA-seq analyses. Among the most significantly changed pathways is the cell adhesion signaling and upregulation of the adhesion molecule P-selectin⁷⁸. Our data appear to be consistent with findings from blood vessel endothelial cells in which inflammation-induced *S1PR1* deficiency promotes P-selectin expression and enhances leukocyte extravasation^{79,80}. Blocking lymphatic P-selectin signaling reversed the effect of S1P signaling deficiency in promoting Th1/Th2 differentiation in vitro; P-selectin neutralization significantly alleviated tail swelling and tissue inflammation in severe lymphedema. These results demonstrate that the loss of LEC S1P signaling may induce a proinflammatory LEC phenotype with increased expression of adhesion molecules such as P-selectin which, in turn, influences T cell activation and differentiation. While P-selectin is

best known for its role in T cell rolling during immune cell extravasation^{81,82}, recent data indicated that P-selectin may modulate T cell activity through PSGL-1⁸³. In agreement, our data suggested that increased P-selectin expression in *S1pr1*-deficient LECs can promote CD4 T cell accumulation around lymphatic vessels and directly modulate their differentiation and activation; a process that could promote abnormal immune responses in lymphedema. Targeting P-selectin is a promising strategy in treating several inflammatory diseases, such as sickle cell disease and neuroblastoma tumors^{84,85}. Blocking P-selectin may also represent a promising new approach for treating lymphedema involving T cell immunity. Additionally, if this biology patterns human responses, it is possible that P-Selectin-directed therapy may benefit patients at risk for lymphedema progression, such as in the peri-operative period following breast cancer surgery.

Our study has several limitations. Treatments testing 4-DP and α -P-selectin Ab in mice may have also targeted non-lymphatic tissues. To more definitively delineate roles of diminished LEC S1P signaling and increased LEC P-selectin expression in lymphedema, further studies require LEC-specific S1PR1 overexpression or P-selectin knockout models. Future investigations can determine local S1P levels in lymphedema tissue to better evaluate the status of ligand production in this disease. A prior study demonstrated that LEC S1PR1 deficiency delays macrophage clearance following myocardial infarction⁸⁶, and future assessments may prove a similar mechanism also operates in lymphedema pathogenesis.

In summary, our findings provide evidence that abnormal lymphatic S1PR1 signaling, caused by lymphatic injury, promotes pathological CD4 T cell activation, and exacerbates lymphedema progression (**Figure 8**). The evolution of lymphedema is complicated with many cellular interactions and disease mediators changing over an expanded period and in a dynamic manner. For this condition, there are a number of pathological features (e.g., inflammation, fibrosis, adiposity, vascular disease) and clinical endpoints (e.g., limb volume, skin thickness) which can be the focus of new drug and biophysical interventions. In the current effort, we have suggested that reduced S1P signaling in lymphatics may presage the onset of lymphedema and is therefore a potentially useful biomarker of disease risk. The use of P-selectin inhibitors for lymphedema is a promising consideration for future clinical trials.

Acknowledgments

Author contribution: DK, WT, and XJ planned and performed experiments and were responsible for data analysis. RV, JC, SG, SL, TG, SK, YZ, ECS, and EB performed the experiments. TW and MX analyzed the RNA-seq data. JBD, PK, JP, and SR provided intellectual input and reagents. DK, WT, XJ, and MRN conceived the study and wrote the manuscript.

Sources of Funding

This work was supported by National Institutes of Health grants HL141105-4 (to MRN) and HL150583-02 (to XJ)

Disclosures

No disclosures

References

1. Rockson SG. Lymphedema after Breast Cancer Treatment. *N Engl J Med*. 2018;379:1937-1944. doi: 10.1056/NEJMcp1803290
2. Rockson SG. Diagnosis and management of lymphatic vascular disease. *J Am Coll Cardiol*. 2008;52:799-806. doi: 10.1016/j.jacc.2008.06.005
3. Kataru RP, Baik JE, Park HJ, Wiser I, Rehal S, Shin JY, Mehrara BJ. Regulation of Immune Function by the Lymphatic System in Lymphedema. *Front Immunol*. 2019;10:470. doi: 10.3389/fimmu.2019.00470
4. Li CY, Kataru RP, Mehrara BJ. Histopathologic Features of Lymphedema: A Molecular Review. *Int J Mol Sci*. 2020;21. doi: 10.3390/ijms21072546
5. Mehrara BJ, Park HJ, Kataru RP, Bromberg J, Coriddi M, Baik JE, Shin J, Li C, Cavalli MR, Encarnacion EM, et al. Pilot Study of Anti-Th2 Immunotherapy for the Treatment of Breast Cancer-Related Upper Extremity Lymphedema. *Biology (Basel)*. 2021;10. doi: 10.3390/biology10090934
6. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology, and disease. *J Cell Biol*. 2011;193:607-618. doi: 10.1083/jcb.201012094
7. Oliver G, Kipnis J, Randolph GJ, Harvey NL. The Lymphatic Vasculature in the 21(st) Century: Novel Functional Roles in Homeostasis and Disease. *Cell*. 2020;182:270-296. doi: 10.1016/j.cell.2020.06.039
8. Petrova TV, Koh GY. Biological functions of lymphatic vessels. *Science*. 2020;369. doi: 10.1126/science.aax4063
9. Tewalt EF, Cohen JN, Rouhani SJ, Engelhard VH. Lymphatic endothelial cells - key players in regulation of tolerance and immunity. *Front Immunol*. 2012;3:305. doi: 10.3389/fimmu.2012.00305
10. Kim KW, Song JH. Emerging Roles of Lymphatic Vasculature in Immunity. *Immune Netw*. 2017;17:68-76. doi: 10.4110/in.2017.17.1.68
11. Rouhani SJ, Eccles JD, Tewalt EF, Engelhard VH. Regulation of T-cell Tolerance by Lymphatic Endothelial Cells. *J Clin Cell Immunol*. 2014;5. doi: 10.4172/2155-9899.1000242
12. Randolph GJ, Ivanov S, Zinselmeyer BH, Scallan JP. The Lymphatic System: Integral Roles in Immunity. *Annu Rev Immunol*. 2017;35:31-52. doi: 10.1146/annurev-immunol-041015-055354
13. Tewalt EF, Cohen JN, Rouhani SJ, Guidi CJ, Qiao H, Fahl SP, Conaway MR, Bender TP, Tung KS, Vella AT, et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. *Blood*. 2012;120:4772-4782. doi: 10.1182/blood-2012-04-427013
14. Dubrot J, Duraes FV, Potin L, Capotosti F, Brighthouse D, Suter T, LeibundGut-Landmann S, Garbi N, Reith W, Swartz MA, et al. Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4(+) T cell tolerance. *J Exp Med*. 2014;211:1153-1166. doi: 10.1084/jem.20132000
15. Podgrabinska S, Kamalu O, Mayer L, Shimaoka M, Snoeck H, Randolph GJ, Skobe M. Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism. *J Immunol*. 2009;183:1767-1779. doi: 10.4049/jimmunol.0802167
16. Cartier A, Hla T. Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. *Science*. 2019;366. doi: 10.1126/science.aar5551
17. Don-Doncow N, Zhang Y, Matuskova H, Meissner A. The emerging alliance of sphingosine-1-phosphate signalling and immune cells: from basic mechanisms to implications in hypertension. *Br J Pharmacol*. 2019;176:1989-2001. doi: 10.1111/bph.14381
18. Mendelson K, Evans T, Hla T. Sphingosine 1-phosphate signalling. *Development*. 2014;141:5-9. doi: 10.1242/dev.094805

- 688 19. Blaho VA, Hla T. Regulation of mammalian physiology, development, and disease by
689 the sphingosine 1-phosphate and lysophosphatidic acid receptors. *Chem Rev.*
690 2011;111:6299-6320. doi: 10.1021/cr200273u
- 691 20. Blaho VA, Hla T. An update on the biology of sphingosine 1-phosphate receptors. *J*
692 *Lipid Res.* 2014;55:1596-1608. doi: 10.1194/jlr.R046300
- 693 21. Paik JH, Skoura A, Chae SS, Cowan AE, Han DK, Proia RL, Hla T. Sphingosine 1-
694 phosphate receptor regulation of N-cadherin mediates vascular stabilization. *Genes*
695 *Dev.* 2004;18:2392-2403. doi: 10.1101/gad.1227804
- 696 22. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'afi RI, Hla
697 T. Vascular endothelial cell adherens junction assembly and morphogenesis induced
698 by sphingosine-1-phosphate. *Cell.* 1999;99:301-312. doi: 10.1016/s0092-
699 8674(00)81661-x
- 700 23. Cartier A, Leigh T, Liu CH, Hla T. Endothelial sphingosine 1-phosphate receptors
701 promote vascular normalization and antitumor therapy. *Proc Natl Acad Sci U S A.*
702 2020;117:3157-3166. doi: 10.1073/pnas.1906246117
- 703 24. Akhter MZ, Chandra Joshi J, Balaji Ragunathrao VA, Maienschein-Cline M, Proia RL,
704 Malik AB, Mehta D. Programming to S1PR1(+) Endothelial Cells Promotes
705 Restoration of Vascular Integrity. *Circ Res.* 2021;129:221-236. doi:
706 10.1161/CIRCRESAHA.120.318412
- 707 25. Yanagida K, Hla T. Vascular and Immunobiology of the Circulatory Sphingosine 1-
708 Phosphate Gradient. *Annu Rev Physiol.* 2017;79:67-91. doi: 10.1146/annurev-
709 physiol-021014-071635
- 710 26. Geng X, Yanagida K, Akwii RG, Choi D, Chen L, Ho Y, Cha B, Mahamud MR,
711 Berman de Ruiz K, Ichise H, et al. S1PR1 regulates the quiescence of lymphatic
712 vessels by inhibiting laminar shear stress-dependent VEGF-C signaling. *JCI Insight.*
713 2020;5. doi: 10.1172/jci.insight.137652
- 714 27. Tabibiazar R, Cheung L, Han J, Swanson J, Beilhack A, An A, Dadras SS, Rockson N,
715 Joshi S, Wagner R, et al. Inflammatory manifestations of experimental lymphatic
716 insufficiency. *PLoS Med.* 2006;3:e254. doi: 10.1371/journal.pmed.0030254
- 717 28. Zollner TM, Asadullah K. Selectin and selectin ligand binding: a bittersweet attraction.
718 *J Clin Invest.* 2003;112:980-983. doi: 10.1172/JCI19962
- 719 29. Jiang X, Tian W, Granucci EJ, Tu AB, Kim D, Dahms P, Pasupneti S, Peng G, Kim Y,
720 Lim AH, et al. Decreased lymphatic HIF-2alpha accentuates lymphatic remodeling in
721 lymphedema. *J Clin Invest.* 2020;130:5562-5575. doi: 10.1172/JCI136164
- 722 30. Weiler MJ, Cribb MT, Nepiyushchikh Z, Nelson TS, Dixon JB. A novel mouse tail
723 lymphedema model for observing lymphatic pump failure during lymphedema
724 development. *Sci Rep.* 2019;9:10405. doi: 10.1038/s41598-019-46797-2
- 725 31. Kim D, Kim M, Kim TW, Choe YH, Noh HS, Jeon HM, Kim H, Lee Y, Hur G, Lee KM,
726 et al. Lymph node fibroblastic reticular cells regulate differentiation and function of
727 CD4 T cells via CD25. *J Exp Med.* 2022;219. doi: 10.1084/jem.20200795
- 728 32. Kim DE, Lee Y, Kim M, Lee S, Jon S, Lee SH. Bilirubin nanoparticles ameliorate
729 allergic lung inflammation in a mouse model of asthma. *Biomaterials.* 2017;140:37-44.
730 doi: 10.1016/j.biomaterials.2017.06.014
- 731 33. Pham TH, Baluk P, Xu Y, Grigorova I, Bankovich AJ, Pappu R, Coughlin SR,
732 McDonald DM, Schwab SR, Cyster JG. Lymphatic endothelial cell sphingosine
733 kinase activity is required for lymphocyte egress and lymphatic patterning. *J Exp Med.*
734 2010;207:17-27. doi: 10.1084/jem.20091619
- 735 34. Peres M, Montfort A, Andrieu-Abadie N, Colacios C, Segui B. S1P: the elixir of life for
736 naive T cells. *Cell Mol Immunol.* 2018;15:657-659. doi: 10.1038/cmi.2017.110
- 737 35. Huang WC, Nagahashi M, Terracina KP, Takabe K. Emerging Role of Sphingosine-1-
738 phosphate in Inflammation, Cancer, and Lymphangiogenesis. *Biomolecules.*
739 2013;3:408-434. doi: 10.3390/biom3030408
- 740 36. Garcia Nores GD, Ly CL, Cuzzzone DA, Kataru RP, Hespe GE, Torrisi JS, Huang JJ,

- Gardenier JC, Savetsky IL, Nitti MD, et al. CD4(+) T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema. *Nat Commun*. 2018;9:1970. doi: 10.1038/s41467-018-04418-y
37. Gousopoulos E, Proulx ST, Scholl J, Uecker M, Detmar M. Prominent Lymphatic Vessel Hyperplasia with Progressive Dysfunction and Distinct Immune Cell Infiltration in Lymphedema. *Am J Pathol*. 2016;186:2193-2203. doi: 10.1016/j.ajpath.2016.04.006
38. Tokumoto M, Tanaka H, Tauchi Y, Tamura T, Toyokawa T, Kimura K, Muguruma K, Yashiro M, Maeda K, Hirakawa K, et al. Immunoregulatory Function of Lymphatic Endothelial Cells in Tumor-draining Lymph Nodes of Human Gastric Cancer. *Anticancer Res*. 2017;37:2875-2883. doi: 10.21873/anticancer.11640
39. Card CM, Yu SS, Swartz MA. Emerging roles of lymphatic endothelium in regulating adaptive immunity. *J Clin Invest*. 2014;124:943-952. doi: 10.1172/JCI73316
40. Saravia J, Chapman NM, Chi H. Helper T cell differentiation. *Cell Mol Immunol*. 2019;16:634-643. doi: 10.1038/s41423-019-0220-6
41. Ruterbusch M, Pruner KB, Shehata L, Pepper M. In Vivo CD4(+) T Cell Differentiation and Function: Revisiting the Th1/Th2 Paradigm. *Annu Rev Immunol*. 2020;38:705-725. doi: 10.1146/annurev-immunol-103019-085803
42. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). *Annu Rev Immunol*. 2010;28:445-489. doi: 10.1146/annurev-immunol-030409-101212
43. Zhang H, Watanabe R, Berry GJ, Nadler SG, Goronzy JJ, Weyand CM. CD28 Signaling Controls Metabolic Fitness of Pathogenic T Cells in Medium and Large Vessel Vasculitis. *J Am Coll Cardiol*. 2019;73:1811-1823. doi: 10.1016/j.jacc.2019.01.049
44. Wen Z, Shen Y, Berry G, Shahram F, Li Y, Watanabe R, Liao YJ, Goronzy JJ, Weyand CM. The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway. *Sci Transl Med*. 2017;9. doi: 10.1126/scitranslmed.aal3322
45. Cohen JN, Tewalt EF, Rouhani SJ, Buonomo EL, Bruce AN, Xu X, Bekiranov S, Fu YX, Engelhard VH. Tolerogenic properties of lymphatic endothelial cells are controlled by the lymph node microenvironment. *PLoS One*. 2014;9:e87740. doi: 10.1371/journal.pone.0087740
46. Iftakhar EKI, Fair-Makela R, Kukkonen-Macchi A, Elima K, Karikoski M, Rantakari P, Miyasaka M, Salmi M, Jalkanen S. Gene-expression profiling of different arms of lymphatic vasculature identifies candidates for manipulation of cell traffic. *Proc Natl Acad Sci U S A*. 2016;113:10643-10648. doi: 10.1073/pnas.1602357113
47. Ni ZY, Walcheck B. Cutaneous lymphocyte-associated antigen (CLA) T cells up-regulate P-selectin ligand expression upon their activation. *Clin Immunol*. 2009;133:257-264. doi: 10.1016/j.clim.2009.07.010
48. Nakayama F, Teraki Y, Kudo T, Togayachi A, Iwasaki H, Tamatani T, Nishihara S, Mizukawa Y, Shiohara T, Narimatsu H. Expression of cutaneous lymphocyte-associated antigen regulated by a set of glycosyltransferases in human T cells: involvement of alpha1, 3-fucosyltransferase VII and beta1,4-galactosyltransferase I. *J Invest Dermatol*. 2000;115:299-306. doi: 10.1046/j.1523-1747.2000.00032.x
49. Sloboda DD, Brooks SV. Treatment with selectin blocking antibodies after lengthening contractions of mouse muscle blunts neutrophil accumulation but does not reduce damage. *Physiol Rep*. 2016;4. doi: 10.14814/phy2.12667
50. Aspelund A, Robciuc MR, Karaman S, Makinen T, Alitalo K. Lymphatic System in Cardiovascular Medicine. *Circ Res*. 2016;118:515-530. doi: 10.1161/CIRCRESAHA.115.306544
51. Brakenhielm E, Alitalo K. Cardiac lymphatics in health and disease. *Nat Rev Cardiol*. 2019;16:56-68. doi: 10.1038/s41569-018-0087-8

- 794 52. Zhou Y, Huang C, Hu Y, Xu Q, Hu X. Lymphatics in Cardiovascular Disease.
795 *Arterioscler Thromb Vasc Biol.* 2020;40:e275-e283. doi:
796 10.1161/ATVBAHA.120.314735
- 797 53. Yeo KP, Lim HY, Angeli V. Leukocyte Trafficking via Lymphatic Vessels in
798 Atherosclerosis. *Cells.* 2021;10. doi: 10.3390/cells10061344
- 799 54. Milasan A, Smaani A, Martel C. Early rescue of lymphatic function limits
800 atherosclerosis progression in Ldlr(-/-) mice. *Atherosclerosis.* 2019;283:106-119. doi:
801 10.1016/j.atherosclerosis.2019.01.031
- 802 55. Balasubramanian D, Lopez Gelston CA, Rutkowski JM, Mitchell BM. Immune cell
803 trafficking, lymphatics and hypertension. *Br J Pharmacol.* 2019;176:1978-1988. doi:
804 10.1111/bph.14370
- 805 56. Vieira JM, Norman S, Villa Del Campo C, Cahill TJ, Barnette DN, Gunadasa-Rohling
806 M, Johnson LA, Greaves DR, Carr CA, Jackson DG, et al. The cardiac lymphatic
807 system stimulates resolution of inflammation following myocardial infarction. *J Clin*
808 *Invest.* 2018;128:3402-3412. doi: 10.1172/JCI97192
- 809 57. Houck P, Dandapantula H, Hardegree E, Massey J. Why We Fail at Heart Failure:
810 Lymphatic Insufficiency Is Disregarded. *Cureus.* 2020;12:e8930. doi:
811 10.7759/cureus.8930
- 812 58. Donnan MD, Kenig-Kozlovsky Y, Quaggin SE. The lymphatics in kidney health and
813 disease. *Nature Reviews Nephrology.* 2021. doi: 10.1038/s41581-021-00438-y
- 814 59. Jiang X, Tian W, Nicolls MR, Rockson SG. The Lymphatic System in Obesity, Insulin
815 Resistance, and Cardiovascular Diseases. *Front Physiol.* 2019;10:1402. doi:
816 10.3389/fphys.2019.01402
- 817 60. Jiang X, Nicolls MR, Tian W, Rockson SG. Lymphatic Dysfunction, Leukotrienes, and
818 Lymphedema. *Annu Rev Physiol.* 2018;80:49-70. doi: 10.1146/annurev-physiol-
819 022516-034008
- 820 61. Zampell JC, Yan A, Avraham T, Andrade V, Malliaris S, Aschen S, Rockson SG,
821 Mehrara BJ. Temporal and spatial patterns of endogenous danger signal expression
822 after wound healing and in response to lymphedema. *Am J Physiol Cell Physiol.*
823 2011;300:C1107-1121. doi: 10.1152/ajpcell.00378.2010
- 824 62. Guo S, Yu Y, Zhang N, Cui Y, Zhai L, Li H, Zhang Y, Li F, Kan Y, Qin S. Higher level of
825 plasma bioactive molecule sphingosine 1-phosphate in women is associated with
826 estrogen. *Biochim Biophys Acta.* 2014;1841:836-846. doi:
827 10.1016/j.bbailip.2014.02.005
- 828 63. Tanaka S, Kanazawa I, Sugimoto T. Visceral fat accumulation is associated with
829 increased plasma sphingosine-1-phosphate levels in type 2 diabetes mellitus.
830 *Diabetes Res Clin Pract.* 2018;143:146-150. doi: 10.1016/j.diabres.2018.07.003
- 831 64. Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas L,
832 Rabinovitch M, Zamanian RT, et al. Blocking macrophage leukotriene b4 prevents
833 endothelial injury and reverses pulmonary hypertension. *Sci Transl Med.*
834 2013;5:200ra117. doi: 10.1126/scitranslmed.3006674
- 835 65. Tian W, Rockson SG, Jiang X, Kim J, Begaye A, Shuffle EM, Tu AB, Cribb M,
836 Nepiyushchikh Z, Feroze AH, et al. Leukotriene B(4) antagonism ameliorates
837 experimental lymphedema. *Sci Transl Med.* 2017;9. doi:
838 10.1126/scitranslmed.aal3920
- 839 66. Harle G, Kowalski C, Dubrot J, Brighouse D, Clavel G, Pick R, Bessis N, Niven J,
840 Scheiermann C, Gannage M, et al. Macroautophagy in lymphatic endothelial cells
841 inhibits T cell-mediated autoimmunity. *J Exp Med.* 2021;218. doi:
842 10.1084/jem.20201776
- 843 67. Tindemans I, van Schoonhoven A, KleinJan A, de Bruijn MJ, Lukkes M, van
844 Nimwegen M, van den Branden A, Bergen IM, Corneth OB, van IWF, et al. Notch
845 signaling licenses allergic airway inflammation by promoting Th2 cell lymph node
846 egress. *J Clin Invest.* 2020;130:3576-3591. doi: 10.1172/JCI128310

- 847 68. Gousopoulos E, Proulx ST, Bachmann SB, Scholl J, Dionyssiou D, Demiri E, Halin C,
848 Dieterich LC, Detmar M. Regulatory T cell transfer ameliorates lymphedema and
849 promotes lymphatic vessel function. *JCI Insight*. 2016;1:e89081. doi:
850 10.1172/jci.insight.89081
- 851 69. Szabo PA, Miron M, Farber DL. Location, location, location: Tissue resident memory
852 T cells in mice and humans. *Sci Immunol*. 2019;4. doi: 10.1126/sciimmunol.aas9673
- 853 70. Park CO, Kupper TS. The emerging role of resident memory T cells in protective
854 immunity and inflammatory disease. *Nat Med*. 2015;21:688-697. doi:
855 10.1038/nm.3883
- 856 71. Mueller SN, Mackay LK. Tissue-resident memory T cells: local specialists in immune
857 defence. *Nat Rev Immunol*. 2016;16:79-89. doi: 10.1038/nri.2015.3
- 858 72. Zundler S, Becker E, Spocinska M, Slawik M, Parga-Vidal L, Stark R, Wiendl M,
859 Atreya R, Rath T, Leppkes M, et al. Hobit- and Blimp-1-driven CD4(+) tissue-resident
860 memory T cells control chronic intestinal inflammation. *Nat Immunol*. 2019;20:288-
861 300. doi: 10.1038/s41590-018-0298-5
- 862 73. Turner DL, Goldklang M, Cvetkovski F, Paik D, Trischler J, Barahona J, Cao M, Dave
863 R, Tanna N, D'Armiento JM, et al. Biased Generation and In Situ Activation of Lung
864 Tissue-Resident Memory CD4 T Cells in the Pathogenesis of Allergic Asthma. *J*
865 *Immunol*. 2018;200:1561-1569. doi: 10.4049/jimmunol.1700257
- 866 74. Ly CL, Nores GDG, Kataru RP, Mehrara BJ. T helper 2 differentiation is necessary for
867 development of lymphedema. *Transl Res*. 2019;206:57-70. doi:
868 10.1016/j.trsl.2018.12.003
- 869 75. Vokali E, Yu SS, Hirose S, Rincon-Restrepo M, F VD, Scherer S, Cortesy-
870 Henrioud P, Kilarski WW, Mondino A, Zehn D, et al. Lymphatic endothelial cells prime
871 naive CD8(+) T cells into memory cells under steady-state conditions. *Nat Commun*.
872 2020;11:538. doi: 10.1038/s41467-019-14127-9
- 873 76. Saxena V, Li L, Paluskievicz C, Kasinath V, Bean A, Abdi R, Jewell CM, Bromberg JS.
874 Role of lymph node stroma and microenvironment in T cell tolerance. *Immunol Rev*.
875 2019;292:9-23. doi: 10.1111/imr.12799
- 876 77. Chakraborty P, Vaena SG, Thyagarajan K, Chatterjee S, Al-Khami A, Selvam SP,
877 Nguyen H, Kang I, Wyatt MW, Baliga U, et al. Pro-Survival Lipid Sphingosine-1-
878 Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity. *Cell Rep*.
879 2019;28:1879-1893 e1877. doi: 10.1016/j.celrep.2019.07.044
- 880 78. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules.
881 *FASEB J*. 1995;9:866-873.
- 882 79. Ruiz M, Frej C, Holmer A, Guo LJ, Tran S, Dahlback B. High-Density Lipoprotein-
883 Associated Apolipoprotein M Limits Endothelial Inflammation by Delivering
884 Sphingosine-1-Phosphate to the Sphingosine-1-Phosphate Receptor 1. *Arterioscler*
885 *Thromb Vasc Biol*. 2017;37:118-129. doi: 10.1161/ATVBAHA.116.308435
- 886 80. Perry HM, Huang L, Ye H, Liu C, Sung SJ, Lynch KR, Rosin DL, Bajwa A, Okusa MD.
887 Endothelial Sphingosine 1-Phosphate Receptor-1 Mediates Protection and Recovery
888 from Acute Kidney Injury. *J Am Soc Nephrol*. 2016;27:3383-3393. doi:
889 10.1681/ASN.2015080922
- 890 81. Ley K, Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues and sites
891 of inflammation. *Nat Rev Immunol*. 2004;4:325-335. doi: 10.1038/nri1351
- 892 82. Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet
893 critical hurdle for successful cancer immunotherapy. *Lab Invest*. 2017;97:669-697.
894 doi: 10.1038/labinvest.2017.25
- 895 83. Tinoco R, Carrette F, Barraza ML, Otero DC, Magana J, Bosenberg MW, Swain SL,
896 Bradley LM. PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell
897 Exhaustion. *Immunity*. 2016;44:1470. doi: 10.1016/j.immuni.2016.05.011
- 898 84. Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-
899 Madden J, Alvarez OA, Gordeuk VR, et al. Crizanlizumab for the Prevention of Pain

900 Crises in Sickle Cell Disease. *N Engl J Med*. 2017;376:429-439. doi:
901 10.1056/NEJMoa1611770
902 85. Nolo R, Herbrich S, Rao A, Zweidler-McKay P, Kannan S, Gopalakrishnan V.
903 Targeting P-selectin blocks neuroblastoma growth. *Oncotarget*. 2017;8:86657-86670.
904 doi: 10.18632/oncotarget.21364
905 86. Li Q, Zhou C, Zhao K, Duan Y, Yue J, Liu X, Wu J, Deng S. Lymphatic endothelial
906 sphingosine 1-phosphate receptor 1 enhances macrophage clearance via lymphatic
907 system following myocardial infarction. *Front Cardiovasc Med*. 2022;9:872102. doi:
908 10.3389/fcvm.2022.872102
909

Figure 1. S1PR1 signaling of LECs is reduced in both mouse and human lymphedema skin.

(A) Acquired lymphedema was surgically induced in the tails of C57BL/6J mice through thermal ablation of lymphatic trunks. Skin incision, alone, was performed in sham surgery groups. (B) RT-qPCR analysis of *Sphk1* mRNA levels in tail skin from control sham surgery mice or animals subjected to lymphatic surgery (n = 4 per each group). (C) Representative immunofluorescence (IF) staining of SPHK1 (red) and LYVE1 (green) of the skin tissues harvested from control or lymphedema mice. DAPI (blue) stains for the nucleus. Scale bar = 40 μ m. (D) Quantification of the SPHK1 staining intensity comparing groups shown in C (n \geq 3 per each group). (E) RT-qPCR analysis of *S1pr1* mRNA levels in tail skin from control sham surgery mice or lymphedema mice (n = 4 per each group). (F and G) Flow cytometry histograms show the mean fluorescence intensity of S1PR1 on LEC (Gp38⁺CD31⁺) population. Representative (F) and compiling data (G) are shown (n \geq 3 per each group). (H and I) The serum concentration of S1P in mouse (H) and human (I) lymphedema (n = 10 per each group). (J) Representative IF staining of Gp38 (green) and S1PR1 (red) of the human skin from healthy control or lymphedema. DAPI (blue) stains for the nucleus. Scale bar = 50 μ m. (K) Quantification of the S1PR1 intensity comparing groups shown in J (n = 4 per each group). Data are presented as mean \pm SEM; * p < 0.05, ** p < 0.01, and **** p < 0.0001 by the Mann-Whitney test.

Figure 2. LEC-specific *S1pr1* deficiency exaggerates tissue swelling, augments cutaneous skin thickness, promotes lymphatic leakage, and reduces lymphatic drainage.

(A) Schematic diagram of the experimental protocol. (B) Quantification of tail volume changes over time of WT and *S1pr1*^{LECKO} mice after lymphatic surgery (n \geq 5 per each group). (C) Representative photographs of tails 21d following lymphatic surgery. (D) A cartoon showing the cross-section view of mouse-tail skin with or without lymphedema. (E to G) H&E staining of tail cross-section 21d following lymphatic surgery. Representative images (E) are shown. Black arrows indicate lymphatic vessel areas. Double-headed black arrows demonstrate cutaneous thickness. Quantification of cutaneous thickness (F) and lymphatic vessel luminal areas (G) are shown (n = 4 per each group). Scale bar = 1 mm. (H and I) Immunofluorescent images of LYVE1 (red) of tail skin 21d after surgery. Representative image (H) and quantification of the LYVE1 area data (I) are shown (n \geq 3 per each group). DAPI (blue) stains the nucleus. Scale bar = 100 μ m. (J) A cartoon showing one side of the mouse tail with two-line lymphatic trunks. (K and L) Near-infrared imaging 21d following lymphatic surgery after ICG injection near the tip of the tail. Representative images (K) are shown. White arrows denote surgical sites. Red arrows indicate ICG drainage. Yellow arrows indicate ICG leakage. Scale bar = 0.5 cm. Quantification of leakage (L) is shown (n = 4 per each group). Data are presented as the mean \pm SEM; * p < 0.05 and ** p < 0.01 by the Mann-Whitney test. ICG; indocyanine green.

Figure 3. LEC *S1pr1* deficiency promotes CD4 T cell infiltration following lymphatic surgery.

(A) Flow cytometric gating scheme for determining tail skin immune cell populations. Flow cytometric analysis was performed d21 after lymphatic surgery. (B-G) Quantification of CD45⁺ cells (B), CD8⁺ T cells (C), CD4⁺ T cells (D), CD4⁺IFN- γ ⁺ Th1 cells (E), CD4⁺IL-4⁺ Th2 cells (F), and Foxp3⁺CD25⁺CD4⁺ Treg cells (G) in tail skin (n \geq 4 per each group). (H)

Representative IF staining of CD4 (red) and LYVE1 (green) of the lymphedema mouse tail skin from WT or *S1pr1*^{LECKO} mice. DAPI (blue) stains for the nucleus. Arrows indicate CD4 T cells surrounding lymphatic vessels. Scale bar = 50 μ m. **(I)** Quantification of the CD4 T cell staining presented in H ($n \geq 5$ per each group). Data are presented as mean \pm SEM; * $p < 0.05$, ** $p < 0.01$, and ns (not significant) by the Mann-Whitney test.

Figure 4. Decreased S1PR1 signaling in LECs promotes T cell activation.

(A) Schematic diagram of LEC (Gp38⁺CD31⁺) purification. **(B)** Representative flow cytometry sorting strategy for the isolation of LECs from cultured lymph node stromal cells. **(C)** Timeline of co-culture with purified LECs and naïve CD4 T cells activating with α -CD3/28 Abs. LECs to T cell ratio was 1:5. **(D-F)** Flow cytometric analysis was performed d4 after co-culture. Representative flow cytometric plots and quantification of IFN- γ ⁺CD44⁺ in CD4⁺ T cells (D), IL-4⁺CD44⁺ in CD4⁺ T cells (E), and Foxp3⁺CD25⁺ in CD4⁺ T cells (F) ($n \geq 6$ per each group). Data are presented as mean \pm SEM; * $p < 0.05$ and ** $p < 0.01$ by the Mann-Whitney test.

Figure 5. Abnormal lymphatic S1PR1 signaling activates lymphocytes through direct cell-cell contact.

(A) Timeline of the co-culture of purified naïve CD4 T cells and HDLECs. **(B)** shCtrl or shS1PR1-treated HDLECs were co-cultured with purified human naïve CD4 T cells activating with α -CD3/28 Abs. LEC to T cell ratio was 1:5. **(C to E)** After 3 days of culture, human CD4 T cells were intracellularly stained for IFN- γ , IL-4, and Foxp3. Representative flow cytometric plots and quantification of IFN- γ ⁺CD44⁺ in CD4⁺ T cells (C), IL-4⁺CD44⁺ in CD4⁺ T cells (D), and Foxp3⁺CD25⁺ T cells (E) ($n \geq 4$ per each group). **(F to J)** T cell-related cytokines were detected in supernatant from co-cultured cells ($n = 7$ per each group). **(K)** HDLECs treated with shCtrl or shS1PR1 were co-cultured with human naïve CD4 T cells in 0.4 μ m membrane pore trans-well in the presence of α -CD3/28 antibody for 3 days. **(L and M)** Representative flow cytometric plots (L) and compiling data (M) of intracellular IFN- γ ⁺ and IL-4⁺ cells in the CD4⁺ T cell population cultured in a trans-well system ($n \geq 5$ per each group). **(N)** Representative flow cytometric plots intracellular Foxp3⁺CD25⁺ T cells in a trans-well system. ($n \geq 4$ per each group). Data are presented as mean \pm SEM; * $p < 0.05$ and ns (not significant) by the Mann-Whitney test for C, D, and L; by Wilcoxon matched-pairs signed rank test for E, F, G, H, and I.

Figure 6. The effects of abnormal S1PR1 signaling on lymphatic biology.

(A and B) Timeline of HDLEC treatment and harvesting time point. RNA was extracted from HDLEC without (A) or with (B) purified naïve CD4 T cell co-culture with α -CD3/28 Ab stimulation. **(C and D)** Volcano plot identifying genes significantly up-regulated (red) in shS1PR1-treated HDLECs versus shCtrl-treated HDLECs. (C) 18 upregulated genes from HDLECs without CD4 T cell co-culture. (D) 111 upregulated genes from HDLECs with CD4 T cell co-culture. **(E)** Venn diagram shows data summary of differentially up-regulated genes from RNA-seq data comparing shS1PR1-treated HDLECs with or without CD4 T cell co-culture. Threshold of false discovery rate < 0.05 . **(F)** KEGG pathway enrichment analysis of differentially up-regulated gene between shCtrl-treated HDLEC and shS1PR1-treated HDLEC with CD4 T cell co-culture. Most significantly upregulated pathways are shown. **(G)** Timeline of M.O.I. dependence shS1PR1 treatment to HDLECs. **(H and I)** P-selectin fluorescence intensity in HDLECs after S1PR1 knock-down was evaluated by flow


cytometric analysis. Representative (H) and compiling data (I) are shown ($n \geq 4$ per each group). (J and K) Flow cytometric analysis was performed from tail skin of WT and *S1pr1*^{LECKO} mice. Representative flow cytometric plots (J) and quantification of P-selectin⁺ LECs in tail tissue skin (K) ($n \geq 4$ per each group). Data for I are presented as the mean \pm SEM; * $p < 0.05$ and **** $p < 0.0001$ compared with the shCtr-treated HDLECs group; by Ordinary one-way ANOVA. Data for K are presented as the mean \pm SEM; ** $p < 0.01$ compared with the WT group; by Mann-Whitney test. KEGG; Kyoto Encyclopedia of Genes and Genomes. M.O.I.; multiplicity of infection.

Figure 7. Blocking P-selectin decreases CD4 T cell activation and lymphedema.


(A) Timeline of the co-culture of purified naïve CD4 T cells and HDLEC. α -human P-selectin Ab (Waps12.2) was added to sh*S1PR1*-treated HDLECs 1h before purified memory CD4 T cell co-culture with HDLECs at day 4. (B and C) Flow cytometric analysis was performed d3 after co-culture. Quantification of IFN- γ ⁺CD44⁺ in CD4⁺ T cells (B), IL-4⁺CD44⁺ in CD4⁺ T cells (C) ($n = 4$ per each group). (D) Schematic diagram of the experimental protocol. 5 mg/kg anti-mouse P-selectin Ab (RB40.34.4) or Isotype IgG control (Iso IgG Ctr) was retro-orbital-i.v. injected into *S1pr1*^{LECKO} mice 1 day before lymphedema surgery and the tail size of animals was measured at days 0, 7, 14, and 21. (E and F) Quantification of tail volume changes (E) ($n \geq 7$ per each group). Representative photographs of tail skin on day 21 after surgery (F). (G) Quantification of IFN- γ ⁺CD44⁺, IL-4⁺CD44⁺, and CD25^{hi} in CD4⁺ T cells from tail skin 21 day after lymphedema surgery ($n \geq 5$ per each group). Data B and C are presented as the mean \pm SEM; **** $p < 0.0001$, # $p < 0.05$, ### $p < 0.001$, and #### $p < 0.0001$ compared with the sh*S1PR1*-treated HDLEC group; by Ordinary one-way ANOVA. Data in E and G are presented as mean \pm SEM; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, and ns (not significant) compared with the *S1pr1*^{LECKO} + Iso Ctr group; by Ordinary one-way ANOVA.

Figure 8. LEC S1PR1 signaling in lymphedema pathogenesis.


Graphic abstract showing how abnormal lymphatic endothelial cell (LEC) S1P signaling can induce T cell activation and lymphedema after lymphatic injury. Lymphatic injury caused LEC S1P-S1PR1 signaling reduction. These changes collectively induce P-selectin expression on LECs resulting in CD4 T cell overactivation.




1036




1037




1038




1039




1040





1041




1042




A**D****E**

WT ***S1pr1*^{LECKO}**

**F**

WT ***S1pr1*^{LECKO}**

**G**

WT ***S1pr1*^{LECKO}**

H

WT ***S1pr1*^{LECKO}**

I

WT ***S1pr1*^{LECKO}**

J

WT ***S1pr1*^{LECKO}**

K

Sham **WT** ***S1pr1*^{LECKO}**

L

WT ***S1pr1*^{LECKO}**

M





WT ***S1pr1*^{LECKO}**










N

















WT ***S1pr1*^{LECKO}**


O



WT ***S1pr1*^{LECKO}**





A**B****C****D****E****F****G****H****I****J****K****L****M**





Genotype	Tx
WT	Iso IgG Ctr
<i>S1pr1</i> ^{LECKO}	Iso IgG Ctr
<i>S1pr1</i> ^{LECKO}	α -P-selectin Ab

